Company
Overview
Leadership
Social Accountability
Technology
RJX Technology
Therapeutic Areas
Pipeline
Clinical Trials
Contact
Contact Us
Join Reven
News
Latest News
Research
Investor Portal
2019/01/15 Reven News Press
January 15, 2019
| Featured
MAD Cohort 3 completed dosing on January 15, 2019.
More Reven News Releases
|
More Research & Development